SRR934906
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.512
- G2M_CHECKPOINT+0.510
- HEDGEHOG_SIGNALING+0.429
- MITOTIC_SPINDLE+0.412
- MYC_TARGETS_V1+0.383
- GLYCOLYSIS+0.337
- HYPOXIA+0.329
- ANGIOGENESIS+0.328
- MTORC1_SIGNALING+0.306
- WNT_BETA_CATENIN_SIGNALING+0.295
Top 10 suppressed
- KRAS_SIGNALING_DN-0.244
- BILE_ACID_METABOLISM-0.177
- XENOBIOTIC_METABOLISM-0.172
- PEROXISOME-0.133
- APICAL_SURFACE-0.126
- SPERMATOGENESIS-0.122
- ESTROGEN_RESPONSE_LATE-0.114
- ESTROGEN_RESPONSE_EARLY-0.095
- ANDROGEN_RESPONSE-0.090
- MYOGENESIS-0.075
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 1F4CD8D0-E2FD-45AA-8CE2-8C0488916778 | — | — | 0.855 |
| 2 | 726D58A7-23E0-492A-B5CE-15DCB11B0C90 | — | — | 0.852 |
| 3 | 113340B4-B092-4B8C-8A13-5932525B0C33 | — | — | 0.836 |
| 4 | SRR15030851 | — | — | 0.828 |
| 5 | BS_23QW0BBA | high-grade glioma | — | 0.827 |
| 6 | 9970B75F-7AC6-431B-BDBB-120D01582CBE | — | — | 0.823 |
| 7 | TCGA-FD-A6TH-01A-11R-A32O-07 | — | — | 0.818 |
| 8 | 50DE1FDE-B85E-4677-B0F8-08275DA41A6E | — | — | 0.812 |
| 9 | A21476BD-0550-4D87-80EA-6E1454E0896D | — | — | 0.809 |
| 10 | SRR934890 | — | — | 0.806 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.512 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.510 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.429 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.412 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.383 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.337 | Inavolisib | — uncovered |
| HYPOXIA | 0.329 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.328 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.306 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.295 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.287 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.255 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.252 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.230 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.221 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.198 | Inavolisib | — uncovered |
| APOPTOSIS | 0.186 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.168 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.154 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.150 | Remibrutinib | — uncovered |